1 April 2017 - The 1 April 2017 issue of the Schedule of Pharmaceutical Benefits sees a number of new & revised listings.

The new & revised listings are:

• Abatacept (Orencia) - new formulation
  
• Brentuximab vedotin (Adcetris) - new indications
• Calcipotriol with betamethasone dipropionate (Enstilar) - new formulation
  
• Cobimetinib hemifumarate (Cotellic) - new medicine
  
• Epoprostenol sodium (Flolan) - new formulation
  
• Etanercept (Brenzys) - new formulation
  
• Paliperidone palmitate (Invega Trinza) - new formulation
  
• Vemurafenib (Zelboraf) - new medicine
  
• Vismodegib (Erivedge) - new medicine
  

Read Summary of Changes